Phase III trial of doxorubicin plus cyclophosphamide ( AC ) , docetaxel , and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer : Japan Clinical Oncology Group trial ( JCOG 9802 )

@inproceedings{Katsumata2009PhaseIT,
  title={Phase III trial of doxorubicin plus cyclophosphamide ( AC ) , docetaxel , and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer : Japan Clinical Oncology Group trial ( JCOG 9802 )},
  author={Noriyuki Katsumata and Tomoki Watanabe and Hidenao Minami and Kenjiro Aogi and Toshio Tabei and Maiko Sano and Norikazu Masuda and Joycelyn Andoh and Tetsuo Ikeda and Takashi Shibata and Sei-ichi Takashima},
  year={2009}
}
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802) N. Katsumata*, T. Watanabe, H. Minami, K. Aogi, T. Tabei, M. Sano, N. Masuda, J. Andoh, T. Ikeda, T. Shibata & S. Takashima Department of Medical Oncology, National Cancer Center Hospital, Tokyo; Department of Medical Oncology, Hamamatsu Oncology Center, Hamamatsu; Department of Medicine… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Similar Papers

Loading similar papers…